Computational Toxicology Approaches at the US Food and Drug Administration

被引:20
|
作者
Yang, Chihae [1 ]
Valerio, Luis G., Jr. [2 ]
Arvidson, Kirk B. [1 ]
机构
[1] US FDA, Off Food Addit Safety, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA
[2] US FDA, Off Pharmaceut Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA
来源
关键词
computational toxicology; database; knowledgebase; QSAR; risk assessment; safety assessment; SAR; TOXICITY HAZARD IDENTIFICATION; COMPREHENSIVE MODEL; GENETIC TOXICITY; MDL-QSAR; E-STATE; DATABASES; CHEMICALS; RODENTS; PHARMACEUTICALS; PREDICTION;
D O I
10.1177/026119290903700509
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
For over a decade, the United States Food and Drug Administration (US FDA) has been engaged in the applied research, development, and evaluation of computational toxicology methods used to support the safety evaluation of a diverse set of regulated products. The basis for evaluating computational toxicology methods is multi-factorial, including the potential for increased efficiency, reduction in the numbers of animals used, lower costs, and the need to explore emerging technologies that support the goals of the US FDA's Critical Path Initiative (e.g. to make decision support information available early in the drug review process). The US FDA's efforts have been facilitated by agency-approved data-sharing agreements between government and commercial software developers. This commentary review describes former and current scientific initiatives at the agency, in the area of computational toxicology methods. In particular, toxicology-based QSAR models, ToxML databases and knowledgebases will be addressed. Notably, many of the computational toxicology tools available are commercial products - however, several are emerging as non-commercial products, which are freely-available to the public, and which will facilitate the understanding of how these programs work and avoid the "black box" paradigm. Through productive collaborations, the US FDA Center for Drug Evaluation and Research, and the Center for Food Safety and Applied Nutrition, have worked together to evaluate, develop and apply these methods to chemical toxicity endpoints of regulatory interest.
引用
收藏
页码:523 / 531
页数:9
相关论文
共 50 条
  • [1] Predictive toxicology for regulatory decisions: Implementing new approaches at US Food and Drug Administration
    Fitzpatrick, Suzanne C.
    [J]. TOXICOLOGY IN VITRO, 2020, 63
  • [2] US Food and Drug Administration regulatory approaches for xenotransplantation products and xenografts
    Arcidiacono, Judith
    [J]. XENOTRANSPLANTATION, 2020, 27 (06) : CP5 - U7
  • [3] US food and drug administration
    Goodman, Jesse
    [J]. ONCOLOGY-NEW YORK, 2006, 20 (08): : 946 - 946
  • [4] US Food and Drug Administration
    Blumenthal, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S37 - S37
  • [5] US Food and Drug Administration Updates
    Sahin, L.
    [J]. BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 748 - 748
  • [6] Transparency at the US Food and Drug Administration
    Califf, Robert M.
    [J]. JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28
  • [7] Independence at the US Food and Drug Administration
    不详
    [J]. LANCET, 2006, 367 (9523): : 1630 - 1630
  • [8] Urokinase and the US food and drug administration
    Ouriel, K
    [J]. JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) : 957 - 958
  • [9] Regulatory use of computational toxicology tools and databases at the United States Food and Drug Administration's Office of Food Additive Safety
    Arvidson, Kirk B.
    Chanderbhan, Ronald
    Muldoon-Jacobs, Kristi
    Mayer, Julie
    Ogungbesan, Adejoke
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (07) : 793 - 796
  • [10] Integrated Drug Reviews at the US Food and Drug Administration
    Woodcock, Janet
    Stein, Peter
    Bugin, Kevin
    [J]. JAMA INTERNAL MEDICINE, 2020, 180 (09) : 1248 - 1250